Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2011-05-24
2011-05-24
Stoica, Elly-Gerald (Department: 1647)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S194100, C514S019300, C530S389700
Reexamination Certificate
active
07947277
ABSTRACT:
The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.
REFERENCES:
patent: 6433155 (2002-08-01), Umansky et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7091321 (2006-08-01), Gillies et al.
patent: 7723477 (2010-05-01), Gurney et al.
patent: 7803783 (2010-09-01), Lee et al.
patent: 2002/0187502 (2002-12-01), Waterman et al.
patent: 2003/0040051 (2003-02-01), Bhanot et al.
patent: 2004/0171559 (2004-09-01), Weissman et al.
patent: 2004/0203003 (2004-10-01), Rhee et al.
patent: 2004/0247593 (2004-12-01), He et al.
patent: 2005/0096263 (2005-05-01), Keay et al.
patent: 2005/0191673 (2005-09-01), Schlegel et al.
patent: 2008/0194457 (2008-08-01), Wands et al.
patent: 2009/0074777 (2009-03-01), Wands et al.
patent: 01/98354 (2001-12-01), None
patent: 02/088081 (2002-11-01), None
patent: 02/092635 (2002-11-01), None
patent: 03/004045 (2003-01-01), None
patent: 2004/032838 (2004-04-01), None
patent: 2004/042028 (2004-05-01), None
patent: 2006/034328 (2006-03-01), None
patent: 2006/036173 (2006-04-01), None
patent: 2006/036175 (2006-04-01), None
patent: 2006055635 (2006-05-01), None
Hsieh et al., Biochemical characterization of Wnt-Frizzled interactions using a soluble, biologically active vertebrate Wnt protein, Proc. Natl. Acad. Sci. USA vol. 96, 3546-3551, 1999.
Recombinant mouse frizzled-4/Fc chimera description from R&D Systems (Cat No. 194-FZ, Nov. 10, 2005).
Blumenthal et al., “The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation”Blood Journal1(3) :965-973 (Aug. 1, 2006).
Yamashita et al, “Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction”FASEB Journal19(9) :1-29 (Jul. 2005).
Yamashita et al., “Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction”The FASEB Journal- FJ Express19(9) :1534-1536 (Sep. 2005).
De Almeida, et al., “The soluble wnt receptor Frizzled8CRD-FC inhibits the growth of teratocarcinomas in vivo”Cancer Research67(11):5371-5379 (Jun. 2007).
Kawano, et al., “Secreted anatagonists of the Wnt signaling pathway”J Cell Science116:2627-2634 (2003).
Kirikoshi et al., “Molecular Cloning and Characterization of Human Frizzled-4 on Chromosome 11q14-q21”Biochem.&Biophys. Res. Comm. 264:955-961 (Nov. 1999).
Zi, et al., “Expression of Frzb/Secreted Frizzled-Related Protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness”Cancer Research65(21) :9762-9770 (Nov. 2005).
Anonymous, “Recombinant Mouse Frizzled-1/Fc Chimera, Catalog No. 1120-FZ”R&D Systems Product Sheet(Online) (Retrived from the internet: http://rndsystems.com/pdf/1120-fz.pdg) (Mar. 20, 2006).
Holcombe et al., “Expression of Wnt ligands and frizzled receptors in colonic mucosa and in colon carcinoma”Molecular Pathology55(4) :220-226 (Aug. 2002).
Milovanovic et al., “Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma”International Journal of Oncology25(5) :1337-1342 (Nov. 2004).
Nakamura et al., “A Wnt- and beta-catenin-dependent pathway for mammalian cardiac myogenesis”Proceedings of the National Academy of Sciences of USA, National Academy of Science,Washington, DC 100(10) :5834-5839 (May 13, 2003).
PCT/ISAInternational Search Reportpp. 1-9 (Sep. 19, 2008) for PCT/US2007/077845, Jun. 23, 2009.
Polakis, Paul, ““Evidence for Wnt Signalling in Cancers lacking Genetic Defects” Therapeutic Opportunities of the Wnt Signalling Pathway in Cancer”NYAS eBriefings Online Adobe Flash Presentation(http:/
yas.org/ebriefreps/ebrief/00541/presentations/polakis/player.html) pp. 1-54 (Oct. 25, 2005).
DeAlmeida Venita I.
Ernst James A.
Polakis Paul
Rubinfeld Bonnee
Genentech Inc.
Stoica Elly-Gerald
LandOfFree
Wnt antagonists and their use in the diagnosis and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wnt antagonists and their use in the diagnosis and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wnt antagonists and their use in the diagnosis and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2660483